Novobiocin

• UNSPSC Description:

  Novobiocin (Albamycin) is a potent and orally active antibiotic. Novobiocin also is a DNA gyrase inhibitor and a heat shock protein 90 (Hsp90) antagonist. Novobiocin has the potential for the research of highly beta-lactam-resistant pneumococcal infections. Novobiocin shows anti-orthopoxvirus activity[1][2][3][4][6].

• Target Antigen:

  Antibiotic; Apoptosis; Bacterial; DNA/RNA Synthesis; HSP; Orthopoxvirus

• Type:

  Natural Products

• Related Pathways:

  Anti-infection;Apoptosis;Cell Cycle/DNA Damage;Metabolic Enzyme/Protease

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Cancer; Infection

• Assay Protocol:

  https://www.medchemexpress.com/novobiocin.html

• Purity:

  95.03

• Solubility:

  10 mM in DMSO

• Smiles:

  CC1=C(O2)C(C(O)=C(NC(C3=CC(C/C=C(C)/C)=C(O)C=C3)=O)C2=O)=CC=C1O[C@H]4[C@@H]([C@@H]([C@@H](OC)C(C)(C)O4)OC(N)=O)O

• Molecular Weight:

  612.62

• References & Citations:

  [4]Eder JP, et al. A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity. Cancer Res. 1991 Jan 15;51(2):510-3. |[5]Bhatia S, et al. Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response.Blood. 2018 Jul 19;132(3):307-320.|[6]Smee DF. Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir Chem Chemother. 2008;19(3):115-24. |[7]Smee DF. Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir Chem Chemother. 2008;19(3):115-24.|[1]Marcu MG, et al. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem. 2000 Nov 24;275(47):37181-6.|[2]Ali-Osman F, et al. Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells. Cancer Res. 1993 Dec 1;53(23):5663-8.|[3]Rodríguez-Cerrato V, et al. Comparative efficacy of novobiocin and amoxicillin in experimental sepsis caused by beta-lactam-susceptible and highly resistant pneumococci. Int J Antimicrob Agents. 2010 Jun;35(6):544-9.Mol Pharm. 2022 Oct 21.|Nat Methods. 2023 Sep;20(9):1388-1399.|Adv Sci (Weinh). 2022 Oct 18;e2203088.|Blood. 2018 Jul 19;132(3):307-320.|Cancer Res Commun. 2024 Apr 9;4(4):1024-1040.|Cell Rep Med. 2024 May 29:101592.|Int J Mol Sci. 2019 Mar 5;20(5). pii: E1125. |Surgery. 2024 Jun 18:S0039-6060(24)00303-9.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  Launched

• CAS Number:

  303-81-1